{"slideshow_credits": null, "snippet": "With the stake in Acerta, the British drug company\u2019s acquisitions this quarter total more than $7 billion. The deal-making reflects pipeline challenges and price pressure.", "abstract": null, "section_name": "Business Day", "print_page": null, "document_type": "article", "byline": {"person": [{"firstname": "Neil", "role": "reported", "lastname": "UNMACK", "rank": 1, "organization": ""}], "original": "NEIL UNMACK"}, "web_url": "http://www.nytimes.com/2015/12/18/business/dealbook/the-logic-in-astrazenecas-buying-spree.html", "lead_paragraph": "With the stake in Acerta, the British drug company\u2019s acquisitions this quarter total more than $7 billion. The deal-making reflects pipeline challenges and price pressure.", "headline": {"main": "The Logic in AstraZeneca\u2019s Buying Spree", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "_id": "567304fd38f0d85bed90f336", "word_count": "367", "multimedia": [], "pub_date": "2015-12-18T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "1"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "2"}, {"name": "organizations", "value": "AstraZeneca PLC", "is_major": "N", "rank": "3"}, {"name": "glocations", "value": "Europe", "is_major": "N", "rank": "4"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}